Fibrocell Science, which developed the first FDA-approved personalized cell therapy for wrinkle reduction, secured $45 million in a private stock sale. The maker of Laviv will use the money to upgrade its production capacity and to develop other applications for the treatment, including as a therapy for burn scars.